BiotechTube
ResQ Biotech

ResQ Biotech

Helsinki, Europe - Other· Est.
resqbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2017 and based in Helsinki, Finland, with significant R&D operations in Patras, Greece, ResQ Biotech is a private, pre-clinical stage company targeting protein misfolding diseases. Its core technology enables high-throughput screening of combinatorial peptide and natural product libraries to identify inhibitors of pathological protein aggregation. Led by a scientifically strong team, including an ERC grantee, the company is advancing its lead program, Project AlphaSyn, against Parkinson's disease while exploring other neurodegenerative indications.

Neurodegenerative DiseasesParkinson's DiseaseAlzheimer's DiseaseAmyotrophic Lateral Sclerosis

Technology Platform

Proprietary platform for rapid production and screening of vast molecular libraries, including combinatorial cyclic peptides and natural products from marine organisms, to identify inhibitors of protein misfolding and aggregation.

Opportunities

The large and growing unmet need for disease-modifying therapies in neurodegenerative diseases presents a multi-billion dollar market opportunity.
The company's parallel path to develop a neuroprotective nutritional supplement could provide earlier, non-dilutive revenue and validate its compounds' bioactivity.
Strong academic ties and success in securing prestigious non-dilutive grants (e.g., ERC) provide a solid foundation for early R&D.

Risk Factors

High scientific risk associated with the historically difficult target of inhibiting protein aggregation in the brain.
Operational and scaling risks as a small, geographically distributed start-up.
Intense competition from larger, well-funded pharmaceutical companies pursuing similar mechanisms.

Competitive Landscape

ResQ operates in a highly competitive space dominated by large pharma and well-funded biotechs targeting protein misfolding in neurodegeneration (e.g., Biogen, Roche, AbbVie, and numerous startups). Its differentiation lies in its specific platform focusing on cyclic peptides and Greek marine natural products, and its dual therapeutic/nutraceutical strategy for Parkinson's disease.

More companies in Neuroscience & CNS →More companies in Europe - Other →